Neurostimulation an extra bonus for Johnson & Johnson in Guidant deal
This article was originally published in Clinica
Guidant's expertise in implantable micro-electronics, developed for use in pacemakers, has been untapped in other therapy fields. It looks like that could change. While the two clear attractions for Johnson & Johnson in its $25.4bn takeover deal for Guidant are the latter's cardiac rhythm management and stent delivery technologies, Guidant's know-how also lends itself to the as yet under-penetrated neurostimulation market, as its New Jersey-based acquirer has already acknowledged.